A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease

作者：Lock Kevin; Wilson Koo; Murphy Daniel^*; Antonio Riesco Juan

来源：Expert Opinion on Pharmacotherapy, 2011, 12(17): 2613-2626.

DOI：10.1517/14656566.2011.628935

• COPD
• cost-effectiveness
• smoking cessation

Objectives: Smoking is an important risk factor in chronic obstructive pulmonary disease (COPD). A recent clinical trial demonstrated the efficacy of varenicline versus placebo as an aid to smoking cessation in patients with COPD. This study examines the cost-effectiveness of varenicline from the perspective of the healthcare systems of Spain (base case), the UK, France, Germany, Greece and Italy.
Methods: A Markov model was developed to determine the cost-effectiveness of varenicline as an aid to smoking cessation, compared to a placebo, in a COPD population. Cost-effectiveness was determined by the incremental cost per quality-adjusted life year (QALY) gained.
Results: In the Spanish base case varenicline had an incremental cost of (sic)1021/person for an average of 0.24 life years (0.17 QALYs), gained over the lifetime of a cohort of COPD patients, resulting in an incremental cost-effectiveness ratio (ICER) of (sic)5,566. In the other European countries, the ICER varied between (sic)4,519 (UK) and (sic)10,167 (Italy). Probabilistic sensitivity analysis suggested varenicline had a high probability (>95%) of being cost-effective at a threshold of (sic)30,000/QALY.
Conclusions: Varenicline is expected to be a cost-effective aid to smoking cessation in COPD patients in all of the countries studied.

• 出版日期2011-12